BAM
TXG icon

Belpointe Asset Management’s 10x Genomics TXG Stock Holding History

Belpointe Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16
Closed -$583 – 3852
2022
Q4 		$583 Buy
+16
New +$523 ﹤0.01% 3522
2021
Q4 		– Sell
-924
Closed -$135K – 1252
2021
Q3 		$135K Buy
+924
New +$159K 0.01% 1031

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Belpointe Asset Management's TXG Position: Q1 2023 in Review

Belpointe Asset Management sold out of 10x Genomics (TXG) in Q1 2023, closing a stake of 16 shares — an estimated $583 sold.

Belpointe Asset Management first reported a position in TXG in Q3 2021 and held it in 2 quarters. The position peaked at $135K in Q3 2021. 258 funds tracked by Wall St. Rank hold TXG as of Q1 2023.

  • Belpointe Asset Management reported no remaining 10x Genomics position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 16 10x Genomics shares in Q1 2023, an estimated $583.
  • Belpointe Asset Management first reported a position in 10x Genomics in Q3 2021 and held it in 2 quarters.
  • Belpointe Asset Management's 10x Genomics position peaked at $135K in Q3 2021.
  • 258 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.